



Another project brought to you by

**Genome**Canada

---

## **Synthetic Antibody Program: Commercial Reagents and Novel Therapy**

<b>Integrated GE<sup>3</sup>LS Project</b>	Distributive Justice and the Allocation of Synthetic Antibodies
<b>Genome Centre</b>	Ontario Genomics Institute
<b>Project Leaders</b>	Sachdev Sidhu and Charles Boone
<b>GE<sup>3</sup>LS Project Leaders</b>	Kerry Bowman, Mount Sinai Hospital

---

### **Project Description**

The GE<sup>3</sup>LS component of this project will examine the ethical implications of the large-scale production of synthetic antibodies in relation to distributive justice. Distributive justice is a principle that evaluates distribution of resources to give maximum value to those in need. Distributive justice does not mean a simple division of all resources. Distributive justice concerns the fair distribution of scarce resources among all socioeconomic groups and population sectors. The question of distributive justice is a key ethical consideration in all aspects of medical care.

GE<sup>3</sup>LS researchers will investigate the financial burdens placed on Canadians with cancer and consult with advocacy groups and other key experts about different models for fair and socially just drug distribution.

Data will be shared with the Canadian Cancer Society and other cancer agencies to enable planning and to improve patient care and patient advocacy strategies. The results will also be shared with all cancer-related groups and Ministries of Health. Importantly, the distributive justice model will help the commercialization committee make decisions about the most effective and just modes of distribution of therapeutic synthetic antibodies.